Identification of eight novel proteasome variants in five unrelated cases of proteasome-associated autoinflammatory syndromes (PRAAS)
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Mutations in genes coding for proteasome subunits and/or proteasome assembly helpers typically cause recurring autoinflammation referred to as chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE) or proteasome-associated autoinflammatory syndrome (PRAAS). Patients with CANDLE/PRAAS present with mostly chronically elevated type I interferon scores that emerge as a consequence of increased proteotoxic stress by mechanisms that are not fully understood. Here, we report on five unrelated patients with CANDLE/PRAAS carrying novel inherited proteasome missense and/or nonsense variants. Four patients were compound heterozygous for novel pathogenic variants in the known CANDLE/PRAAS associated genes, PSMB8 and PSMB10, whereas one patient showed additive loss-of-function mutations in PSMB8. Variants in two previously not associated proteasome genes, PSMA5 and PSMC5, were found in a patient who also carried the PSMB8 founder mutation, p.T75M. All newly identified mutations substantially impact the steady-state expression of the affected proteasome subunits and/or their incorporation into mature 26S proteasomes. Our observations expand the spectrum of PRAAS-associated genetic variants and improve a molecular diagnosis and genetic counseling of patients with sterile autoinflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among these, neurodevelopmental proteasomopathies have emerged as a complex group of syndromes caused by defects in genes related to key proteasome systems, such as the ubiquitin–proteasome system (UPS) and the previously mentioned 26S proteasome [5,6].”
From Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506 · cited 1×
“The UPS is a constitutively active process (2) involved in the rapid elimination of a large variety of protein substrates, which are typically modified with ubiquitin chains and are subsequently degraded by the 26S proteasomes into shorter peptides (3).”
BackgroundMechanisms Underlying Ubiquitination
Pickart, C. M. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.503 · Cited by 3,184 · cited 1×
“The conjugation of protein substrates with ubiquitin moieties requires the coordinated action of the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzymes, and the E3 ubiquitin ligases (4).”
BackgroundPolyubiquitin chains: polymeric protein signals
Pickart, C. M., & Fushman, D. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.09.009 · Cited by 1,049
Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
Seifert, U., Bialy, L. P., Ebstein, F., Bech-Otschir, D., Voigt, A., Schröter, F., Prozorovski, T., Lange, N., Steffen, J., Rieger, M., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.036 · Cited by 551 · cited 1×
“Frontiers in Immunology 10 conditions when supply of additional proteasome components is limited by the mutant alleles (34).”
BackgroundSelf-citationJAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Sanchez, G. A. M., Reinhardt, A., Ramsey, S., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murias, S., Dare, J. A., Brown, D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98814 · Cited by 536 · cited 1×
“A pathogenic role of type I IFN in CANDLE/PRAAS has been validated by blocking type I IFN signaling with Janus kinase (JAK) 1/2 (JAK1/2)-specific tyrosine kinase inhibitors, which results in clinical remission in 50% of patients associated with normalization of the IFN scores in these patients with mostly PSMB8 mutati…”
Self-citationSmith, D. M., Chang, S.-C., Park, S., Finley, D., Cheng, Y., & Goldberg, A. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.033 · Cited by 521
Self-citationHuber, E. M., Basler, M., Schwab, R., Heinemeyer, W., Kirk, C. J., Groettrup, M., & Groll, M. (2012) · Cell · doi:10.1016/j.cell.2011.12.030 · Cited by 483 · cited 1×
“Three-dimensional, spatial in silico mapping of all mutated residues within the 20S and 19S particles (30) (PDB, entry code 3UNH) (31) (PDB, entry code 5LN3) shows the physical interaction sites of b5i/LMP7/PSMB8 and a5/PSMA5 at the a/b-ring interface (Figure 2A).”
BackgroundLiu, Y., Ramot, Y., Torrelo, A., Paller, A. S., Si, N., Babay, S., Kim, P. W., Sheikh, A., Lee, C. R., Chen, Y., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33368 · Cited by 406
Self-citationThe Ubiquitin System, Autophagy, and Regulated Protein Degradation
Varshavsky, A. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044859 · Cited by 403 · cited 1×
“Protein breakdown is ensured by two main cellular degradation machineries: the ubiquitin-proteasome system (UPS) and the autophagy lysosomal system (1).”
BackgroundBrehm, A., Liu, Y., Sheikh, A., Marrero, B., Omoyinmi, E., Zhou, Q., Montealegre, G., Biancotto, A., Reinhardt, A., Almeida de Jesus, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81260 · Cited by 344 · cited 5×
“In situations when loss-of-function mutations allow for incorporation of a mutant allele with residual function in compound heterozygosity or when present in a digenic inheritance model, the WT protein encoded from the WT allele gets incorporated and forms an altered proteasome that often has reduced but sufficient fu…”
BackgroundInfluentialSelf-citationAgarwal, A. K., Xing, C., DeMartino, G. N., Mizrachi, D., Hernandez, M. D., Sousa, A. B., Martínez de Villarreal, L., dos Santos, H. G., & Garg, A. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.10.031 · Cited by 335
Arima, K., Kinoshita, A., Mishima, H., Kanazawa, N., Kaneko, T., Mizushima, T., Ichinose, K., Nakamura, H., Tsujino, A., Kawakami, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106015108 · Cited by 327
A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans
Kitamura, A., Maekawa, Y., Uehara, H., Izumi, K., Kawachi, I., Nishizawa, M., Toyoshima, Y., Takahashi, H., Standley, D. M., Tanaka, K., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58414 · Cited by 308
The Ubiquitin–Proteasome System in Immune Cells
Çetin, G., Klafack, S., Studencka-Turski, M., Krüger, E., & Ebstein, F. (2021) · Biomolecules · doi:10.3390/biom11010060 · Cited by 209
Self-citationDevelopment of a Validated Interferon Score Using NanoString Technology
Kim, H., de Jesus, A. A., Brooks, S. R., Liu, Y., Huang, Y., VanTries, R., Montealegre Sanchez, G. A., Rotman, Y., Gadina, M., & Goldbach-Mansky, R. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0127 · Cited by 190 · cited 1×
“Gene expression of selected genes was determined by NanoString (NanoString Technologies, Seattle, WA), and a 28gene type I IFN score was calculated as previously described (25).”
MethodSelf-citationEmerging roles of immunoproteasomes beyond MHC class I antigen processing
Ebstein, F., Kloetzel, P., Krüger, E., & Seifert, U. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0938-0 · Cited by 170 · cited 2×
“inherited from his asymptomatic father, has been reported in one heterozygous subject in the gnomAD database (7) (Figure 1A and Supplementary Figure 2A).”
BackgroundSelf-citationPoli, M. C., Ebstein, F., Nicholas, S. K., de Guzman, M. M., Forbes, L. R., Chinn, I. K., Mace, E. M., Vogel, T. P., Carisey, A. F., Benavides, F., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.04.010 · Cited by 168
Self-citationHexameric assembly of the proteasomal ATPases is templated through their C termini
Park, S., Roelofs, J., Kim, W., Robert, J., Schmidt, M., Gygi, S. P., & Finley, D. (2009) · Nature · doi:10.1038/nature08065 · Cited by 137
Self-citationInsights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus
Kim, H., Sanchez, G. A. M., & Goldbach-Mansky, R. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1465-5 · Cited by 133
Self-citationType I interferonopathies in pediatric rheumatology
Volpi, S., Picco, P., Caorsi, R., Candotti, F., & Gattorno, M. (2016) · Pediatric Rheumatology · doi:10.1186/s12969-016-0094-4 · Cited by 131 · cited 1×
“A common pathological feature of CANDLE/PRAAS is the presence of a sterile type I interferon (IFN) gene signature with persistent expression of typical IFN-induced genes (ISGs) in peripheral blood (19, 20).”
BackgroundCANDLE Syndrome As a Paradigm of Proteasome-Related Autoinflammation
Torrelo, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00927 · Cited by 131 · cited 1×
“02 elevated temperature (CANDLE) syndrome (9, 10).”
de Jesus, A. A., Brehm, A., VanTries, R., Pillet, P., Parentelli, A.-S., Montealegre Sanchez, G. A., Deng, Z., Paut, I. K., Goldbach-Mansky, R., & Krüger, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.12.1012 · Cited by 114
Self-citationKüry, S., Besnard, T., Ebstein, F., Khan, T. N., Gambin, T., Douglas, J., Bacino, C. A., Craigen, W. J., Sanders, S. J., Lehmann, A., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.01.003 · Cited by 110 · cited 7×
“This hypothesis was later challenged, as NDD and only few systemic inflammatory findings have been reported in patients carrying mutations in the 20S subunit b6 encoded by PSMB1 (39).”
BackgroundInfluentialSelf-citationMolecular Details Underlying Dynamic Structures and Regulation of the Human 26S Proteasome
Wang, X., Cimermancic, P., Yu, C., Schweitzer, A., Chopra, N., Engel, J. L., Greenberg, C., Huszagh, A. S., Beck, F., Sakata, E., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.065326 · Cited by 110 · cited 1×
“Three-dimensional, spatial in silico mapping of all mutated residues within the 20S and 19S particles (30) (PDB, entry code 3UNH) (31) (PDB, entry code 5LN3) shows the physical interaction sites of b5i/LMP7/PSMB8 and a5/PSMA5 at the a/b-ring interface (Figure 2A).”
BackgroundRole of Proteasomes in Inflammation
Goetzke, C. C., Ebstein, F., & Kallinich, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081783 · Cited by 82 · cited 1×
“02 elevated temperature (CANDLE) syndrome (9, 10).”
Self-citationDysfunction in protein clearance by the proteasome: impact on autoinflammatory diseases
Brehm, A., & Krüger, E. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0486-4 · Cited by 79
Self-citationEbstein, F., Poli Harlowe, M. C., Studencka-Turski, M., & Krüger, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02756 · Cited by 79 · cited 1×
“These observations support a proteasome complex– phenotype association with deficiencies of 19S or 20S complexes causing NDD or PRAAS, respectively (38).”
MethodSelf-citationPSMB10, the last immunoproteasome gene missing for PRAAS
Sarrabay, G., Méchin, D., Salhi, A., Boursier, G., Rittore, C., Crow, Y., Rice, G., Tran, T.-A., Cezar, R., Duffy, D., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.024 · Cited by 65 · cited 1×
“Phe14Ser (16), has previously been reported in homozygosity in an Algerian boy; the p.”
BackgroundDavidson, S., Yu, C.-H., Steiner, A., Ebstein, F., Baker, P. J., Jarur-Chamy, V., Hrovat Schaale, K., Laohamonthonkul, P., Kong, K., Calleja, D. J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi6763 · Cited by 64 · cited 1×
“In a recent study, protein kinase R (PKR) was defined as an innate immune sensor for proteotoxic stress via interaction with accumulated IL-24 to promote dysregulated type I IFN signaling (42).”
BackgroundSelf-citationDisease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome
Boyadzhiev, M., Marinov, L., Boyadzhiev, V., Iotova, V., Aksentijevich, I. A., & Hambleton, S. (2019) · Pediatric Rheumatology · doi:10.1186/s12969-019-0322-9 · Cited by 56 · cited 1×
“A pathogenic role of type I IFN in CANDLE/PRAAS has been validated by blocking type I IFN signaling with Janus kinase (JAK) 1/2 (JAK1/2)-specific tyrosine kinase inhibitors, which results in clinical remission in 50% of patients associated with normalization of the IFN scores in these patients with mostly PSMB8 mutati…”
Ansar, M., Ebstein, F., Özkoç, H., Paracha, S. A., Iwaszkiewicz, J., Gesemann, M., Zoete, V., Ranza, E., Santoni, F. A., Sarwar, M. T., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa032 · Cited by 44
Self-citationKataoka, S., Kawashima, N., Okuno, Y., Muramatsu, H., Miwata, S., Narita, K., Hamada, M., Murakami, N., Taniguchi, R., Ichikawa, D., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.010 · Cited by 43
Kumar, B., Kim, Y. C., & Demartino, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153627 · Cited by 39
Brehm, A., Liu, Y., Sheikh, A., Marrero, B., Omoyinmi, E., Zhou, Q., Montealegre, G., Biancotto, A., Reinhardt, A. L., de Jesus, A. A., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86020 · Cited by 39
Self-citationPSMD12 haploinsufficiency in a neurodevelopmental disorder with autistic features
Khalil, R., Kenny, C., Hill, R. S., Mochida, G. H., Nasir, R., Partlow, J. N., Barry, B. J., Al‐Saffar, M., Egan, C., Stevens, C. R., et al. (2018) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32688 · Cited by 39 · cited 7×
“This hypothesis was later challenged, as NDD and only few systemic inflammatory findings have been reported in patients carrying mutations in the 20S subunit b6 encoded by PSMB1 (39).”
BackgroundInfluentialEbstein, F., Küry, S., Most, V., Rosenfelt, C., Scott-Boyer, M.-P., van Woerden, G. M., Besnard, T., Papendorf, J. J., Studencka-Turski, M., Wang, T., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3189 · Cited by 36 · cited 1×
“These results indicate that, despite different organ manifestations, the molecular mechanisms driving the clinically different disease manifestations are similar but may act in a tissue specific manner (43).”
BackgroundSelf-citationVerhoeven, D., Schonenberg‐Meinema, D., Ebstein, F., Papendorf, J. J., Baars, P. A., van Leeuwen, E. M. M., Jansen, M. H., Lankester, A. C., van der Burg, M., Florquin, S., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.07.039 · Cited by 35 · cited 3×
“Patient 1 who has a mutation in the constitutive proteasome component, PSMA5, requires combination treatment of a JAKi with tocilizumab due to more JAKi refractory disease reminiscent of what is seen in patients with mutations in other constitutive proteasome components, PSMB4 and PSMA3; interestingly, the combination…”
BackgroundSelf-citationHaploinsufficiency of PSMD12 Causes Proteasome Dysfunction and Subclinical Autoinflammation
Yan, K., Zhang, J., Lee, P. Y., Tao, P., Wang, J., Wang, S., Zhou, Q., & Dong, M. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42070 · Cited by 33 · cited 1×
“Vice versa, disease-causing variants in PSMD12 that leads to more prominent NDD were shown to have a blood IFN signature with subclinical inflammation (40, 41).”
BackgroundImmunoproteasome Function in Normal and Malignant Hematopoiesis
Santamaría, N. T., Ebstein, F., Heidel, F. H., & Krüger, E. (2021) · Cells · doi:10.3390/cells10071577 · Cited by 31
Self-citationPatel, P. N., Hunt, R. D., Pettigrew, Z. J., Shirley, J. B., Vogel, T. P., & de Guzman, M. M. (2021) · Pediatric Dermatology · doi:10.1111/pde.14517 · Cited by 30 · cited 2×
“Frontiers in Immunology 06 Patient 5 has been previously reported (29); a concise description of her disease can be found in the supplements of this paper.”
BackgroundMartinez, C. A., Ebstein, F., Nicholas, S. K., Guzman, M. D., Forbes, L. R., Delmonte, O. M., Bosticardo, M., Castagnoli, R., Krance, R. A., Notarangelo, L. D., et al. (2021) · Blood · doi:10.1182/blood.2021011005 · Cited by 29 · cited 3×
“Patient 1 who has a mutation in the constitutive proteasome component, PSMA5, requires combination treatment of a JAKi with tocilizumab due to more JAKi refractory disease reminiscent of what is seen in patients with mutations in other constitutive proteasome components, PSMB4 and PSMA3; interestingly, the combination…”
BackgroundSelf-citationImmunoproteasomes control activation of innate immune signaling and microglial function
Çetin, G., Studencka‐Turski, M., Venz, S., Schormann, E., Junker, H., Hammer, E., Völker, U., Ebstein, F., & Krüger, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982786 · Cited by 28 · cited 1×
“This phenomenon is well established in mouse models with ablation of PSMB8 (11, 32, 33).”
BackgroundSelf-citationStankiewicz-Isidor syndrome: expanding the clinical and molecular phenotype
Isidor, B., Ebstein, F., Hurst, A., Vincent, M., Bader, I., Rudy, N. L., Cogne, B., Mayr, J., Brehm, A., Bupp, C., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2021.09.005 · Cited by 24
Self-citationChama, L. L. D. F., Ebstein, F., Wiesrecker, B., Wagh, P. R., Hammer, E., Weiß, F. U., Junker, H., Studencka‐Turski, M., Lerch, M. M., Krüger, E., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16682 · Cited by 14
Self-citation
Cited by
Autoinflammatory Diseases: A Review
AN, J. W., Marwaha, A., & Laxer, R. M. (2024) · The Journal of Rheumatology · doi:10.3899/jrheum.2023-1209 · Cited by 77
“31-33 Case 2 discussed above exemplifies a typical interferonop-athy.”
Goldbach‐Mansky, R. T., Alehashemi, S., & de Jesus, A. A. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01184-8 · Cited by 54
“Deleterious null mutations in immunoproteasome subunits can be partially compensated for by their respective constitutive subunits, leading to a milder disease phenotype than mutations affecting constitutive proteasome subunits 185 .”
Self-citationvan der Made, C. I., Kersten, S., Chorin, O., Engelhardt, K. R., Ramakrishnan, G., Griffin, H. R., van der Loeff, I. S., Venselaar, H., Raas‐Rothschild, A., Segev, M., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.02.013 · Cited by 26
Type I interferon pathway in pediatric systemic lupus erythematosus
Zhou, Y., & Song, H. (2024) · World Journal of Pediatrics · doi:10.1007/s12519-024-00811-4 · Cited by 17
“However, it is essential to note that this finding cannot be definitively attributed to the condition, as the patient also possessed a pathogenic maternally inherited PSMB8 variant and a de novo PSMA5 mutation [86].”
BackgroundProteasome disorders and inborn errors of immunity
Poli, M. C. (2023) · Immunological Reviews · doi:10.1111/imr.13299 · Cited by 12
“61 In any case, this approach is often laborious or requires large quantities of biologic material.”
Background
Metadata
- Authors
- Papendorf, J. J., Ebstein, F., Alehashemi, S., Piotto, D. G. P., Kozlova, A., Terreri, M. T., Shcherbina, A., Rastegar, A., Rodrigues, M., Pereira, R., Park, S., Lin, B., Uss, K., Möller, S., da Silva Pina, A. F., Sztajnbok, F., Torreggiani, S., Niemela, J., Stoddard, J., Rosenzweig, S. D., Oler, A. J., McNinch, C., de Guzman, M. M., Fonseca, A., Micheloni, N., Fraga, M. M., Perazzio, S. F., Goldbach-Mansky, R., de Jesus, A. A., & Krüger, E.
- Affiliations
- Universitätsmedizin Greifswald (DE)
- National Institutes of Health (US)
- Universidade Federal de São Paulo (BR)
- Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology (RU)
- Universidade Federal do Rio de Janeiro (BR)
- Universidade Federal de Ciências da Saúde de Porto Alegre (BR)
- Corresponding author
- Krüger, Elke
- ORCID
- Ebstein, Frédéric
- Alehashemi, Sara
- Piotto, Daniela Gerent Petry
- Terreri, Maria Teresa
- Shcherbina, Anna
- Rastegar, Andre
- Rodrigues, Marta
- Pereira, Renan
- Lin, Bin
- Möller, Sophie
- Torreggiani, Sofia
- Niemela, Julie
- Stoddard, Jennifer
- Rosenzweig, Sergio D.
- Oler, Andrew J.
- McNinch, Colton
- Fonseca, Adriana
- Fraga, Melissa Mariti
- Perazzio, Sandro Félix
- Krüger, Elke
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-08-04
- Volume
- 14
- Pages
- 1190104-1190104
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC10436547
- OpenAlex
- W4385580306
- Cited by
- 38
- References
- 44
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 15 · 2023: 1
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- candles, PSMB8, compound heterozygosity, loss-of-function mutations, type I interferon, proteotoxic stress, genetic diagnosis, genetic counseling
- MeSH terms
- Cytoplasm, Dermatitis, Erythema Nodosum, Fingers, Humans, Syndrome, Proteasome Endopeptidase Complex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.